Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin

Journal of Cosmetic Dermatology

Volumn 15, Issue 2, 2016, Pages 131-144

  Pratchyapurit, Walai Orn ^a  

^a Institute of Dermatology Thailand   (Thailand)

Author keywords

diacetyl boldine; hydroquinone; MASI score; melasma; TGF beta 1 biomimetic oligopeptide 68

Indexed keywords

ARBUTIN; ASCORBIC ACID; BEMOTRIZINOL; BISOCTRIZOLE; BOLDINE; DIACETYLBOLDINE; GLYCOLIC ACID; GLYCYRRHIZA EXTRACT; HYDROQUINONE; OLIGOPEPTIDE; SALICYLIC ACID; SUNSCREEN; TGF BETA1 BIOMIMETIC OLIGOPEPTIDE 68; TITANIUM DIOXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHLOASMA; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY SKIN; ERYTHEMA; FACIAL MELASMA; FEMALE; HUMAN; HYPERPIGMENTATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SKIN ATROPHY; SKIN EXFOLIATION; SKIN PIGMENTATION; TELANGIECTASIA; TREATMENT OUTCOME;

EID: 84975073387     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/jocd.12201     Document Type: Article

References (25)

1. Mas-Chamberlin C, Peschard O, Leroux R et al. Di-acetyl-nor-aporphines: novel molecules and novel mechanism to inhibit melanogenesis. SÖFW-Journal 2004; 130: 3–20.
2. Barankin B, Silver SG, Carruthers A. The skin in pregnancy. J Cutan Med Surg 2002; 6: 236–40.
3. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Investig Dermatol Symp Proc 1997; 2: 37–40.
4. Park HY, Yaar M. Disorders of melanocytes: biology of melanocytes. In: L Goldsmith, S Katz, B Gilchrest et al, eds. Fitzpatrick's Dermatology in General Medicine, 8th edn., Vol. 1. New York: McGraw-Hill Professional, 2012: p. 772.
5. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355: 51–65.
6. Brenner M, Hearing VJ. Modifying skin pigmentation – approaches through intrinsic biochemistry and exogenous agents. Drug Discov Today Dis Mech 2008; 5: e189–99.
7. Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol 2004; 36: 1482–91.
8. Park HY, Wu H, Killoran CE et al. The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-beta on melanosomes. J Cell Sci 2004; 117: 3659–68.
9. Draelos ZD, Yatskayer M, Bhushan P et al. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Cutis 2010; 86: 153–8.
10. ™ Technical file. [online] n.d., [cited 2015 March 13]:[33 screens] Available from URL: http://www.lanopearlexport.com/downloads/research/B-White.pdf
11. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc 2008; 13: 20–4.
12. Yokota T, Nishio H, Kubota Y et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigm Cell Res 1998; 11: 355–61.
13. Dong-II J. Melanogenesis inhibitor from paper mulberry. Cosmet Toiletries 1997; 112: 59–62.
14. Bang SH, Han SJ, Kim DH. Hydrolysis of arbutin to hydroquinone by human skin bacteria and its effect on antioxidant activity. J Cosmet Dermatol 2008; 7: 189–93.
15. Picardo M, Carrera M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin 2007; 25: 353–62.
16. Usuki A, Ohashi A, Sato H et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol 2003; 12: 43–50.
17. Kasraee B, Handjani F, Parhizgar A et al. Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology 2005; 211: 360–2.
18. Pandya A, Berneburg M, Ortonne JP et al. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol 2006; 156: 21–8.
19. Kimbrough-Green CK, Griffiths CE, Finkel LJ et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle controlled clinical trial. Arch Dermatol 1994; 130: 727–33.
20. Leenutaphong V, Nettakul A, Rattansuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai 1999; 82: 868–75.
21. Pratchyapruit W, Vashrangsi N, Sindhavananda J et al. Instrumental analysis of the pattern of improvement and that of recurrence of melasma in Thai females treated with Kligman-Willis triple combination therapy: confirmation by using its two different formulae. Skin Res Technol 2011; 17: 226–33.
22. Moncada B, Sahagún-Sánchez LK, Torres-Alvarez B et al. Molecular structure and concentration of melanin in the stratum corneum of patients with melasma. Photodermatol Photoimmunol Photomed 2009; 25: 159–60.
23. Marrakchi S, Maibach HI. Biophysical parameters of skin: map of human face, regional, and age-related differences. Contact Dermatitis 2007; 57: 28–34.
24. Jungman E, Maibach HI. Enhancing sunscreen efficacy in the ‘real’ world? J Dermatol Treat 2010; 21: 261–6.
25. Jeanmougin M, Bouloc A, Schmutz JL. A new sunscreen application technique to protect more efficiently from ultraviolet radiation. Photodermatol Photoimmunol Photomed 2014; 30: 323–31.